Your session is about to expire
← Back to Search
Unknown
ATH-1017 for Alzheimer's Disease
Phase 2 & 3
Waitlist Available
Research Sponsored by Athira Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male subjects and their partners must agree to continue to use a double-barrier method of contraception during the study, including the follow-up period, unless the partner is not of childbearing potential
Be older than 18 years old
Must not have
New diagnosis of severe major depressive disorder even without psychotic features
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 210 weeks
Awards & highlights
Summary
This trial is testing the safety and tolerability of fosgonimeton in Alzheimer's patients who have completed other studies.
Who is the study for?
This trial is for people with mild to moderate Alzheimer's who finished a previous 26-week study of ATH-1017. Participants need a reliable caregiver, must be in good health overall, and men must use contraception. It's not for those who had serious side effects before, have severe depression or psychosis, are at risk of suicide, or were recently diagnosed with cancer (except certain skin or prostate cancers).
What is being tested?
The trial tests the safety and tolerability of fosgonimeton (ATH-1017) in patients with mild to moderate Alzheimer's disease who completed prior studies on this drug. The goal is to see how well they handle the treatment over an extended period.
What are the potential side effects?
While specific side effects aren't listed here, generally the study aims to monitor any adverse reactions from long-term use of ATH-1017 in participants from earlier phases.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a male and will use double contraception during and after the study.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been newly diagnosed with severe depression without psychosis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 210 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~210 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Side effects data
From 2022 Phase 2 trial • 77 Patients • NCT0449100663%
Injection site reaction
22%
Eosinophilia
15%
Injection site vesicles
15%
Fatigue
15%
Headache
15%
Pruritus
11%
Injection site pain
11%
Paraesthesia
11%
Arthralgia
7%
Injection site erythema
7%
Dizziness
7%
Neutrophilia
7%
Fall
7%
Contusion
7%
Post procedural complication
7%
Lipohypertrophy
7%
Pollakiuria
4%
Skin induration
4%
Skin exfoliation
4%
Rash pruritic
4%
Thrombocytopenia
4%
Vertigo
4%
Hip fracture
4%
Injection site induration
4%
Cholinergic syndrome
4%
Injection site paraesthesia
4%
Injection site pruritus
4%
Injection site mass
4%
Chest discomfort
4%
Pain
4%
Flushing
4%
Induration
4%
Immediate post-injection reaction
4%
Application site pruritus
4%
Feeling abnormal
4%
Extensor plantar response
4%
Dementia Alzheimer's type
4%
Syncope
4%
Parosmia
4%
Anaemia
4%
Nausea
4%
Vomiting
4%
Diarrhoea
4%
Toothache
4%
Abdominal pain upper
4%
Wound secretion
4%
Skin abrasion
4%
Joint injury
4%
Pruritus allergic
4%
Hair colour changes
4%
Urticaria
4%
Back pain
4%
Agitation
4%
Disorientation
4%
Delirium
4%
Dysphemia
4%
Electrocardiogram QT prolonged
4%
Eosinophil count increased
4%
White blood cell count increased
4%
Upper respiratory tract infection
4%
Hyperlipidaemia
4%
Hypoglycaemia
4%
Hypotension
4%
Amaurosis fugax
4%
Genital paraesthesia
4%
Pneumonia aspiration
4%
Lung disorder
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
ATH-1017 40 mg
ATH-1017 70 mg
Trial Design
1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Daily subcutaneous (SC) injection of ATH-1017 - 40mg Dosage
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ATH-1017
2020
Completed Phase 2
~110
Find a Location
Who is running the clinical trial?
Athira PharmaLead Sponsor
7 Previous Clinical Trials
871 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a male and will use double contraception during and after the study.I have been newly diagnosed with severe depression without psychosis.I can sign the consent form myself or have someone legally allowed to do it for me.You experience strong and fixed false beliefs or see or hear things that are not really there.I have a newly-diagnosed cancer, but skin or early prostate cancer that's under control doesn't count.You have a high risk of attempting to harm yourself.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger